Journal ArticleOPEN ACCESS

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types

  • Takamatsu S
  • Brown J
  • Yamaguchi K
  • et al.
JCO Precision Oncology (2022) (6)
DOI: 10.1200/po.22.00085
40Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.
Get full text

Abstract

PURPOSEHomologous recombination DNA repair deficiency (HRD) is associated with sensitivity to platinum and poly (ADP-ribose) polymerase inhibitors in certain cancer types, including breast, ovarian...

Cite

CITATION STYLE

APA

Takamatsu, S., Brown, J. B., Yamaguchi, K., Hamanishi, J., Yamanoi, K., Takaya, H., … Matsumura, N. (2022). Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. JCO Precision Oncology, (6). https://doi.org/10.1200/po.22.00085

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free